Free Trial

Ainos (AIMD) Competitors

Ainos logo
$2.58 -0.02 (-0.77%)
As of 04:00 PM Eastern

AIMD vs. ATNM, PRLD, GRCE, LIAN, NBRV, XCUR, OSTX, RANI, SCLX, and MURA

Should you be buying Ainos stock or one of its competitors? The main competitors of Ainos include Actinium Pharmaceuticals (ATNM), Prelude Therapeutics (PRLD), Grace Therapeutics (GRCE), LianBio (LIAN), Nabriva Therapeutics (NBRV), Exicure (XCUR), OS Therapies (OSTX), Rani Therapeutics (RANI), Scilex (SCLX), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical products" industry.

Ainos vs. Its Competitors

Actinium Pharmaceuticals (NYSE:ATNM) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 10.4% of Ainos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Actinium Pharmaceuticals has a beta of -0.32, meaning that its stock price is 132% less volatile than the S&P 500. Comparatively, Ainos has a beta of 2.13, meaning that its stock price is 113% more volatile than the S&P 500.

Ainos has higher revenue and earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actinium PharmaceuticalsN/AN/A-$48.82M-$1.47-1.22
Ainos$20K540.51-$14.86M-$6.45-0.40

Actinium Pharmaceuticals currently has a consensus target price of $4.00, suggesting a potential upside of 123.46%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Actinium Pharmaceuticals is more favorable than Ainos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Actinium Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Ainos
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Ainos' return on equity of -88.07% beat Actinium Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Actinium PharmaceuticalsN/A -100.85% -47.89%
Ainos N/A -88.07%-48.60%

In the previous week, Actinium Pharmaceuticals and Actinium Pharmaceuticals both had 1 articles in the media. Actinium Pharmaceuticals' average media sentiment score of 1.11 beat Ainos' score of 0.63 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Actinium Pharmaceuticals Positive
Ainos Positive

Summary

Actinium Pharmaceuticals beats Ainos on 7 of the 13 factors compared between the two stocks.

Get Ainos News Delivered to You Automatically

Sign up to receive the latest news and ratings for AIMD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AIMD vs. The Competition

MetricAinosMED IndustryMedical SectorNASDAQ Exchange
Market Cap$10.90M$2.50B$5.70B$9.51B
Dividend YieldN/A1.75%4.69%4.01%
P/E Ratio-0.409.0528.0720.05
Price / Sales540.51757.64448.5799.42
Price / CashN/A165.2136.2258.56
Price / Book0.475.168.665.87
Net Income-$14.86M$30.99M$3.25B$258.55M
7 Day Performance-6.86%7.74%4.20%2.23%
1 Month Performance1.67%16.18%10.82%12.76%
1 Year Performance-24.63%-1.03%34.70%19.36%

Ainos Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AIMD
Ainos
1.5558 of 5 stars
$2.58
-0.8%
N/A-24.0%$10.90M$20K-0.4040
ATNM
Actinium Pharmaceuticals
2.4567 of 5 stars
$1.52
-3.5%
$4.00
+164.0%
N/A$47.26MN/A-1.0930Positive News
PRLD
Prelude Therapeutics
3.6967 of 5 stars
$0.81
-0.5%
$4.50
+452.2%
-84.4%$46.24M$7M-0.48120Positive News
GRCE
Grace Therapeutics
2.5508 of 5 stars
$3.19
-3.6%
$12.00
+276.2%
N/A$45.77MN/A-3.58N/APositive News
LIAN
LianBio
N/A$0.42
-0.9%
N/A-82.6%$45.68MN/A-0.52110
NBRV
Nabriva Therapeutics
N/AN/AN/AN/A$45.46M$35.59M0.0070
XCUR
Exicure
1.3417 of 5 stars
$6.85
-2.6%
N/A+1,945.6%$44.41M$500K-1.7950Gap Up
OSTX
OS Therapies
2.0616 of 5 stars
$1.58
+1.3%
$18.00
+1,039.2%
N/A$44.40MN/A-1.84N/AGap Up
RANI
Rani Therapeutics
2.3416 of 5 stars
$0.43
-38.4%
$7.33
+1,605.4%
-82.4%$44.14M$1.03M-0.43110Gap Up
High Trading Volume
SCLX
Scilex
2.3905 of 5 stars
$6.73
+6.5%
$455.00
+6,660.8%
-82.1%$43.93M$56.59M-0.2380News Coverage
MURA
Mural Oncology
3.4217 of 5 stars
$2.49
-2.0%
$12.00
+381.9%
-28.3%$43.86MN/A-0.32119

Related Companies and Tools


This page (NASDAQ:AIMD) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners